effect of N-acetylcysteine in the treatment of peritoneal dialysis and hemodialysis patients
Phase 2
- Conditions
- chronic kidney disease stage 5.Chronic kidney disease, stage 5
- Registration Number
- IRCT2014071418482N1
- Lead Sponsor
- Tehran University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
treating with dialysis for more than 3 months ;having more than 100 mL urine in 24 hours.
Exclusion Criteria
treating with dialysis for less than 3 months; having acute renal failure; being currently treated with antioxidants such as vitamins E, C.; being anuric (less than 100 mL urine in 24 hours).
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 24hr urine volume. Timepoint: days 0, 15, 30, 45, 60, 75, 90. Method of measurement: measuring 24hr urine volume with graded container.;Glomerular filtration rate (GFR). Timepoint: before study (day 0)and at the end of study (day 90). Method of measurement: 24hr urine volume test and evaluating mean of urea and creatinin clearance according to formula in the questionaire.;KT/V. Timepoint: before study (day 0) and at the end of study (day 90). Method of measurement: measuring urea before and after dialysis.
- Secondary Outcome Measures
Name Time Method Fasting plasma glucose. Timepoint: before study and monthly till the end of the study. Method of measurement: laboratory.;Gastrointestinal complication (nausea, vomiting, diarrhea). Timepoint: patients visits. Method of measurement: asking from paitients.